Breast Carcinoma: Updates in Molecular Profiling 2018

Sudeshna Bandyopadhyay; Martin H Bluth; Rouba Ali-Fehmi

doi:10.1016/j.cll.2018.02.006

Breast Carcinoma: Updates in Molecular Profiling 2018

Clin Lab Med. 2018 Jun;38(2):401-420. doi: 10.1016/j.cll.2018.02.006.

Authors

Sudeshna Bandyopadhyay¹, Martin H Bluth², Rouba Ali-Fehmi³

Affiliations

¹ Department of Pathology, Detroit Medical Center, Harper University Hospital 3990 John R, Detroit, MI 48201, USA. Electronic address: SBandyop@dmc.org.
² Department of Pathology, Wayne State University, School of Medicine, 540 East Canfield Street, Detroit, MI 48201, USA; Pathology Laboratories, Michigan Surgical Hospital, 21230 Dequindre Road, Warren, MI 48091, USA.
³ Department of Pathology, Detroit Medical Center, Harper University Hospital 3990 John R, Detroit, MI 48201, USA.

PMID: 29776638
DOI: 10.1016/j.cll.2018.02.006

Abstract

The most significant contribution of molecular subtyping of breast carcinomas has been the identification of estrogen-positive and estrogen-negative tumor subtypes. Knowledge of genetic alterations in these tumors will help clinicians identify novel therapeutic targets. Understanding the progression pathways involved in the transition of in situ carcinoma to invasive carcinoma might lead to efficient risk stratification in these patients. The Cancer Genome Analysis Network has collected genomic and epigenomic data to provide comprehensive information regarding carcinogenesis and pathway interactions. Such information improves understanding of the disease process and also provides more accurate information toward identifying targetable mutations for treatment.

Keywords: Breast; Carcinoma; Genetic alterations; Molecular subtyping.

Publication types

Review

MeSH terms

Breast Neoplasms* / classification
Breast Neoplasms* / diagnosis
Breast Neoplasms* / genetics
Breast Neoplasms* / pathology
Female
Humans
Molecular Diagnostic Techniques